Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for brain diseases.
Based on the provided financial statements, the company did not report any revenue for 2024 or 2025. The basic and diluted net loss per share (EPS) was $(1.45) for the full year 2025, an improvement from $(1.53) in 2024. For the fourth quarter of 2025, the EPS was $(0.35).
Neumora reported a total net loss of $236.9 million for the full year 2025. As of December 31, 2025, the company held $182.5 million in cash, cash equivalents, and marketable securities, which is expected to fund its operations into the third quarter of 2027.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post Neumora Therapeutics 2025 Financial Update first appeared on Alphastreet.
